Group B Engages an Inhibitory Siglec through Sialic Acid Mimicry to Blunt Innate Immune and Inflammatory Responses

English version České info

Group B Streptococcus (GBS) is a common agent of bacterial sepsis and meningitis in newborns. The GBS surface capsule contains sialic acids (Sia) that engage Sia-binding immunoglobulin-like lectins (Siglecs) on leukocytes. Here we use mice lacking Siglec-E, an inhibitory Siglec of myelomonocytic cells, to study the significance of GBS Siglec engagement during in vivo infection. We found GBS bound to Siglec-E in a Sia-specific fashion to blunt NF-κB and MAPK activation. As a consequence, Siglec-E-deficient macrophages had enhanced pro-inflammatory cytokine secretion, phagocytosis and bactericidal activity against the pathogen. Following pulmonary or low-dose intravenous GBS challenge, Siglec-E KO mice produced more pro-inflammatory cytokines and exhibited reduced GBS invasion of the central nervous system. In contrast, upon high dose lethal challenges, cytokine storm in Siglec-E KO mice was associated with accelerated mortality. We conclude that GBS Sia mimicry influences host innate immune and inflammatory responses in vivo through engagement of an inhibitory Siglec, with the ultimate outcome of the host response varying depending upon the site, stage and magnitude of infection.

Vyšlo v časopise: Group B Engages an Inhibitory Siglec through Sialic Acid Mimicry to Blunt Innate Immune and Inflammatory Responses. PLoS Pathog 10(1): e32767. doi:10.1371/journal.ppat.1003846
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1003846

Souhrn

Zdroje

1. EdwardsMS (2006) Issues of antimicrobial resistance in group B streptococcus in the era of intrapartum antibiotic prophylaxis. Semin Pediatr Infect Dis 17 : 149–152.

2. HeathPT, SchuchatA (2007) Perinatal group B streptococcal disease. Best Pract Res Clin Obstet Gynaecol 21 : 411–424.

3. ThigpenMC, WhitneyCG, MessonnierNE, ZellER, LynfieldR, et al. (2011) Bacterial meningitis in the United States, 1998–2007. N Engl J Med 364 : 2016–2025.

4. FerrieriP, ClearyPP, SeedsAE (1977) Epidemiology of group-B streptococcal carriage in pregnant women and newborn infants. J Med Microbiol 10 : 103–114.

5. GalaskRP, VarnerMW, PetzoldCR, WilburSL (1984) Bacterial attachment to the chorioamniotic membranes. Am J Obstet Gynecol 148 : 915–928.

6. PharesCR, LynfieldR, FarleyMM, Mohle-BoetaniJ, HarrisonLH, et al. (2008) Epidemiology of invasive group B streptococcal disease in the United States, 1999–2005. JAMA 299 : 2056–2065.

7. BedfordH, de LouvoisJ, HalketS, PeckhamC, HurleyR, et al. (2001) Meningitis in infancy in England and Wales: follow up at age 5 years. BMJ 323 : 533–536.

8. EdmondKM, KortsalioudakiC, ScottS, SchragSJ, ZaidiAK, et al. (2012) Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 379 : 547–556.

9. BaltimoreRS (2007) Consequences of prophylaxis for group B streptococcal infections of the neonate. Semin Perinatol 31 : 33–38.

10. CastorML, WhitneyCG, Como-SabettiK, FacklamRR, FerrieriP, et al. (2008) Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol 2008 : 727505.

11. SchuchatA (1998) Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin Microbiol Rev 11 : 497–513.

12. EdwardsMS, BakerCJ (2005) Group B streptococcal infections in elderly adults. Clin Infect Dis 41 : 839–847.

13. SkoffTH, FarleyMM, PetitS, CraigAS, SchaffnerW, et al. (2009) Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990–2007. Clin Infect Dis 49 : 85–92.

14. RubensCE, WesselsMR, HeggenLM, KasperDL (1987) Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. Proc Natl Acad Sci U S A 84 : 7208–7212.

15. WesselsMR, RubensCE, BenediVJ, KasperDL (1989) Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule. Proc Natl Acad Sci U S A 86 : 8983–8987.

16. MarquesMB, KasperDL, PangburnMK, WesselsMR (1992) Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun 60 : 3986–3993.

17. TakahashiS, AoyagiY, AddersonEE, OkuwakiY, BohnsackJF (1999) Capsular sialic acid limits C5a production on type III group B streptococci. Infect Immun 67 : 1866–1870.

18. CrockerPR, PaulsonJC, VarkiA (2007) Siglecs and their roles in the immune system. Nat Rev Immunol 7 : 255–266.

19. VarkiA (2007) Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins. Nature 446 : 1023–1029.

20. CaoH, CrockerPR (2011) Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation? Immunology 132 : 18–26.

21. PillaiS, NetravaliIA, CariappaA, MattooH (2012) Siglecs and immune regulation. Annu Rev Immunol 30 : 357–392.

22. VarkiA, AngataT (2006) Siglecs–the major subfamily of I-type lectins. Glycobiology 16 : 1R–27R.

23. PaulSP, TaylorLS, StansburyEK, McVicarDW (2000) Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 96 : 483–490.

24. UlyanovaT, BlasioliJ, Woodford-ThomasTA, ThomasML (1999) The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur J Immunol 29 : 3440–3449.

25. UlyanovaT, ShahDD, ThomasML (2001) Molecular cloning of MIS, a myeloid inhibitory siglec, that binds protein-tyrosine phosphatases SHP-1 and SHP-2. J Biol Chem 276 : 14451–14458.

26. VarkiA (2011) Since there are PAMPs and DAMPs, there must be SAMPs? Glycan “self-associated molecular patterns” dampen innate immunity, but pathogens can mimic them. Glycobiology 21 : 1121–1124.

27. CarlinAF, LewisAL, VarkiA, NizetV (2007) Group B streptococcal capsular sialic acids interact with siglecs (immunoglobulin-like lectins) on human leukocytes. J Bacteriol 189 : 1231–1237.

28. CarlinAF, UchiyamaS, ChangYC, LewisAL, NizetV, et al. (2009) Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. Blood 113 : 3333–3336.

29. ZhangJQ, BiedermannB, NitschkeL, CrockerPR (2004) The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur J Immunol 34 : 1175–1184.

30. BoydCR, OrrSJ, SpenceS, BurrowsJF, ElliottJ, et al. (2009) Siglec-E is up-regulated and phosphorylated following lipopolysaccharide stimulation in order to limit TLR-driven cytokine production. J Immunol 183 : 7703–7709.

31. McMillanSJ, SharmaRS, McKenzieEJ, RichardsHE, ZhangJ, et al. (2013) Siglec-E is a negative regulator of acute pulmonary neutrophil inflammation and suppresses CD11b beta2-integrin-dependent signalling. Blood 121 : 2084–2094.

32. RedelinghuysP, AntonopoulosA, LiuY, Campanero-RhodesMA, McKenzieE, et al. (2011) Early murine T-lymphocyte activation is accompanied by a switch from N-Glycolyl -⁠ to N-acetyl-neuraminic acid and generation of ligands for siglec-E. J Biol Chem 286 : 34522–34532.

33. GergelyJ, PechtI, SarmayG (1999) Immunoreceptor tyrosine-based inhibition motif-bearing receptors regulate the immunoreceptor tyrosine-based activation motif-induced activation of immune competent cells. Immunol Lett 68 : 3–15.

34. ZhangJ, SomaniAK, SiminovitchKA (2000) Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin Immunol 12 : 361–378.

35. TaylorLS, PaulSP, McVicarDW (2000) Paired inhibitory and activating receptor signals. Rev Immunogenet 2 : 204–219.

36. ChangYC, UchiyamaS, VarkiA, NizetV (2012) Leukocyte inflammatory responses provoked by pneumococcal sialidase. MBio 3: e00220–11.

37. AndoM, TuW, NishijimaK, IijimaS (2008) Siglec-9 enhances IL-10 production in macrophages via tyrosine-based motifs. Biochem Biophys Res Commun 369 : 878–883.

38. ChenGY, ChenX, KingS, CavassaniKA, ChengJ, et al. (2011) Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. Nat Biotechnol 29 : 428–435.

39. ShigeokaAO, RoteNS, SantosJI, HillHR (1983) Assessment of the virulence factors of group B streptococci: correlation with sialic acid content. The Journal of infectious diseases 147 : 857–863.

40. WesselsMR, HaftRF, HeggenLM, RubensCE (1992) Identification of a genetic locus essential for capsule sialylation in type III group B streptococci. Infection and immunity 60 : 392–400.

41. RivestS (2009) Regulation of innate immune responses in the brain. Nat Rev Immunol 9 : 429–439.

42. MarianiMM, KielianT (2009) Microglia in infectious diseases of the central nervous system. J Neuroimmune Pharmacol 4 : 448–461.

43. AbbottNJ, PatabendigeAA, DolmanDE, YusofSR, BegleyDJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37 : 13–25.

44. GuptaN, ScharenbergAM, BurshtynDN, WagtmannN, LioubinMN, et al. (1997) Negative signaling pathways of the killer cell inhibitory receptor and Fc gamma RIIb1 require distinct phosphatases. J Exp Med 186 : 473–478.

45. MaedaA, KurosakiM, OnoM, TakaiT, KurosakiT (1998) Requirement of SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2 for paired immunoglobulin-like receptor B (PIR-B)-mediated inhibitory signal. J Exp Med 187 : 1355–1360.

46. OnoM, BollandS, TempstP, RavetchJV (1996) Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature 383 : 263–266.

47. LajauniasF, DayerJM, ChizzoliniC (2005) Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. Eur J Immunol 35 : 243–251.

48. OhtaM, IshidaA, TodaM, AkitaK, InoueM, et al. (2010) Immunomodulation of monocyte-derived dendritic cells through ligation of tumor-produced mucins to Siglec-9. Biochem Biophys Res Commun 402 : 663–669.

49. ClynesR, MaizesJS, GuinamardR, OnoM, TakaiT, et al. (1999) Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med 189 : 179–185.

50. NadlerMJ, McLeanPA, NeelBG, WortisHH (1997) B cell antigen receptor-evoked calcium influx is enhanced in CD22-deficient B cell lines. J Immunol 159 : 4233–4243.

51. O'KeefeTL, WilliamsGT, DaviesSL, NeubergerMS (1996) Hyperresponsive B cells in CD22-deficient mice. Science 274 : 798–801.

52. YuasaT, KuboS, YoshinoT, UjikeA, MatsumuraK, et al. (1999) Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J Exp Med 189 : 187–194.

53. ZhangM, AngataT, ChoJY, MillerM, BroideDH, et al. (2007) Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. Blood 109 : 4280–4287.

54. CrockerPR, McMillanSJ, RichardsHE (2012) CD33-related siglecs as potential modulators of inflammatory responses. Ann N Y Acad Sci 1253 : 102–111.

55. StrleK, ZhouJH, ShenWH, BroussardSR, JohnsonRW, et al. (2001) Interleukin-10 in the brain. Crit Rev Immunol 21 : 427–449.

56. MalipieroU, KoedelU, PfisterHW, LeveenP, BurkiK, et al. (2006) TGFbeta receptor II gene deletion in leucocytes prevents cerebral vasculitis in bacterial meningitis. Brain 129 : 2404–2415.

57. BanerjeeS, BhatMA (2007) Neuron-glial interactions in blood-brain barrier formation. Annu Rev Neurosci 30 : 235–258.

58. WangY, NeumannH (2010) Alleviation of neurotoxicity by microglial human Siglec-11. J Neurosci 30 : 3482–3488.

59. LewisAL, NizetV, VarkiA (2004) Discovery and characterization of sialic acid O-acetylation in group B Streptococcus. Proc Natl Acad Sci USA 101 : 11123–11128.

60. AngataT, VarkiA (2000) Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways. J Biol Chem 275 : 22127–22135.

61. MoussaudS, DraheimHJ (2010) A new method to isolate microglia from adult mice and culture them for an extended period of time. J Neurosci Methods 187 : 243–253.

62. DoranKS, EngelsonEJ, KhosraviA, MaiseyHC, FedtkeI, et al. (2005) Blood-brain barrier invasion by group B Streptococcus depends upon proper cell-surface anchoring of lipoteichoic acid. J Clin Invest 115 : 2499–2507.